Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2010

01-08-2010 | Original Article

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study

Authors: Dominique Koensgen, Guelten Oskay-Oezcelik, Ioanna Katsares, Ulla Walle, Christine Klapp, Alexander Mustea, Dirk Stengel, Franz Porzsolt, Werner Lichtenegger, Jalid Sehouli, on behalf of the Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group “Quality of life”

Published in: Supportive Care in Cancer | Issue 8/2010

Login to get access

Abstract

Goals of work

Quality of life (Qol) represents a relevant end point in the clinical management of advanced ovarian cancer (AOC). However, there exist only a few specific instruments which have been designed for patients with ovarian cancer. The aim of this study was to develop a systematic checklist (Berlin Symptom Checklist Ovary (BSCL-O)) as an instrument of Qol for patients with AOC and to discriminate between the frequency and the importance of symptoms.

Patients and methods

The main symptoms were identified in a phase I study via free interviews of five patients with ovarian cancer (OC) as well as five medical doctors, family dependants, and care workers. In the phase II study, the capability of BSCL-O was evaluated by questionnaire-guided interviews of 200 patients with primary OC, recurrent OC, metastasized breast cancer, and benign ovarian tumors.

Main results

In phase I, 36 main symptoms were identified. In phase II, 7,200 answers from 98.5% of all patients were evaluable. Of the 36 symptoms of the BSCL-O, 23 revealed clinical relevance. There was a correlation of frequency and importance of symptoms (p < 0.05). The symptoms of the BSCL-O were deemed twice as strenuous in patients with recurrent OC.

Conclusions

The BSCL-O can measure Qol of patients with OC. The BSCL-O is being validated in a phase III study.
Literature
1.
Anderson B (1994) Quality of life in progressive ovarian cancer. Gynecol Oncol 55:151–155
2.
Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al (2001) Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19(6):1809–1817PubMed
3.
Bullinger M (1996) Methoden zur Lebensqualitätsbewertung in der Onkologie. Forum Deutsche Krebsgesellschaft 11:210–216
4.
Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748CrossRefPubMed
5.
Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
6.
Coates A, Dillenbeck CF, McNeil DR et al (1983) On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 19:1633–1637CrossRefPubMed
7.
Cull A, Howat S, Greimel E et al (2001) Development of a European organization for research and treatment of cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37:47–53CrossRefPubMed
8.
Ersek M, Ferrell B, Dow K et al (1997) Quality of life in women with ovarian cancer. West J Nurs Res 19:334–350CrossRefPubMed
9.
Fish L, Lewis B (1999) Quality of life issues in the management of ovarian cancer. Semin Oncol 26:32–39PubMed
10.
Greimel ER, Bjelic-Radisic V, Pfisterer J et al (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24(4):579–586CrossRefPubMed
11.
Greimel E, Bottomley A, Cull A et al (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39:1402–1408CrossRefPubMed
12.
13.
Jacobs I, van Nagell J, DePriest P Jr (1998) Screening for epithelial ovarian cancer. In: David M, Gershenson W, Mcguire P (eds) Ovarian cancer: controversies in management. Medical Division of Pearson Professional Limited, New York, pp 1–15
14.
Le T, Leis A, Pahwa P et al (2004) Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment. J Obstet Gynaecol Can 26(7):627–631PubMed
15.
Montazeri A, McEwen J, Gillis C (1996) Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer 4:169–179CrossRefPubMed
16.
Moore DH (1994) Ovarian cancer in the elderly patient. Oncology (Williston Park) 8:21–30
17.
Oskay-Ozcelik G, Sehouli J (2009) Pros and cons for systemic therapy in recurrent ovarian cancer. Anticancer Res 29(7):2831–2836PubMed
18.
19.
Portenoy R, Thaler H, Kornblith A (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefPubMed
20.
Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227CrossRefPubMed
21.
Wenzel L, Huang HQ, Monk BJ et al (2005) Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 23(24):5605–5612CrossRefPubMed
22.
Willemse P, van Lith J, Mulder N (1990) Risk and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer 26:345–352CrossRefPubMed
Metadata
Title
Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study
Authors
Dominique Koensgen
Guelten Oskay-Oezcelik
Ioanna Katsares
Ulla Walle
Christine Klapp
Alexander Mustea
Dirk Stengel
Franz Porzsolt
Werner Lichtenegger
Jalid Sehouli
on behalf of the Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group “Quality of life”
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 8/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0733-0

Other articles of this Issue 8/2010

Supportive Care in Cancer 8/2010 Go to the issue

Letter to the Editor

Increased blood culture sensitivity in pediatric oncology patients: is it the peripheral culture or increased collected blood volume?

Original Article

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

Erratum

Erratum to: Psychosocial distress in acute cancer patients assessed with an expert rating scale

Original Article

Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial

Original Article

Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line

Review Article

Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits